{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:41:52Z","timestamp":1794440512604,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020521","name":"Uppsala Monitoring Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although dolutegravir (DTG)-based HIV treatment has demonstrated superior efficacy, it has been associated with adverse drug reactions (ADRs). Robust pharmacovigilance systems that ensure that received ADRs reports are complete and accurate facilitate timely regulatory decision making. However, there is little research seeking to understand the contexts underpinning data capture of DTG- associated ADRs. We sought to understand barriers to achieving completeness of DTG-associated ADR reports in HIV clinics in Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We adopted a qualitative exploratory research design. Between August and October 2024, we conducted 36 in-depth interviews with HIV clinicians and eight focus groups with people with HIV or PWH (56 participants) in the HIV clinics of 12 purposively selected health facilities across Uganda. Data were analyzed by thematic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our study unearthed patient-based barriers to achieving completeness of data in ADR reports which include the six-monthly appointment spacing intervals for PWH which impede recall of events surrounding ADRs, difficulty by PWH in eliciting details on DTG medication (such as brand and batch numbers), non-disclosure of concurrent use of herbal medicines and the fear by PWH of being switched away from DTG-based therapy which was perceived as superior. Health workforce barriers include a novel finding of \u2018professional agency\u2019 whereby HIV clinicians manage DTG-associated ADRs at an individual-level, fear of inviting scrutiny post-reporting impedes the supply of complete details on ADR reports such as on dosage as well as the low awareness among mid-cadres such as nurses of the importance of providing complete ADR reports in enabling regulatory action. Health system barriers include the reported shortage of in-puts for conducting laboratory investigations of suspected ADRs and limited incentives to reporters for providing complete information on ADR reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Health workers perceived factors underpinning incomplete DTG-associated ADR reports in Uganda as stemming from patient-based factors (e.g. non-disclosure of concomitant use of herbal medicines), health workforce-drivers (e.g. \u2018professional agency\u2019 in responding to ADRs) and health system constraints (lack of incentives for reporting). The policy and programming implications for improving data quality in reporting DTG-associated ADRs in Uganda and countries with similar setting are discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11592-0","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:05:38Z","timestamp":1762164338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding causes of incomplete reports of adverse drug reactions associated with dolutegravir-based HIV treatment in uganda: a qualitative study"],"prefix":"10.1186","volume":"25","author":[{"given":"Henry","family":"Zakumumpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Byomire","family":"Ndagije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanitah","family":"Atuhaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Mayengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Odipiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiguba","family":"Ronald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"11592_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinMed. 2019. https:\/\/doi.org\/10.1016\/j.eclinm.2019.10.001.","journal-title":"EClinMed"},{"issue":"11","key":"11592_CR2","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1111\/bcp.14851","volume":"87","author":"JL Montastruc","year":"2021","unstructured":"Montastruc JL, Lafaurie M, de Canecaude C, Durrieu G, Sommet A, Montastruc F, Bagheri H. Fatal adverse drug reactions: A worldwide perspective in the world health organization pharmacovigilance database. Br J Clin Pharmacol. 2021;87(11):4334\u201340.","journal-title":"Br J Clin Pharmacol"},{"key":"11592_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595.","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"11592_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/picr.PICR_105_17","volume":"9","author":"MM Mahajan","year":"2018","unstructured":"Mahajan MM, Thatte UM, Gogtay NJ, Deshpande S. An analysis of completeness and quality of adverse drug reaction reports at an adverse drug reaction monitoring centre in western India. Perspect Clin Res. 2018;9(3):123.","journal-title":"Perspect Clin Res"},{"key":"11592_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11096-020-01141-x","volume":"43","author":"H Adedeji-Adenola","year":"2021","unstructured":"Adedeji-Adenola H, Nlooto M. Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review. Int J Clin Pharm. 2021;43:11\u201324.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"11592_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low-and middle\u2010income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491\u2013509.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"11592_CR7","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/S2214-109X(17)30489-8","volume":"6","author":"M Stolbrink","year":"2018","unstructured":"Stolbrink M, Mortimer K. Collision of communicable and non-communicable disease epidemics\u2014the case of HIV and COPD. Lancet Global Health. 2018;6(2):e126\u20137.","journal-title":"Lancet Global Health"},{"key":"11592_CR8","unstructured":"Nicholson A, Negussie Y, Shah CM, Ogawa VA. National Academies of Sciences, Engineering, and Medicine. An Overview of Colliding Epidemics and Syndemics. InThe Convergence of Infectious Diseases and Noncommunicable Diseases: Proceedings of a Workshop 2019 Oct 24. National Academies Press (US)."},{"key":"11592_CR9","first-page":"1","volume":"25","author":"R Kiguba","year":"2023","unstructured":"Kiguba, R., Zakumumpa, H., Ndagije, H.B., Mwebaza, N., Ssenyonga, R., Tregunno, P., Harrison, K. and Pirmohamed, M., 2023. Facilitators and barriers to uptake of the med safety mobile app for adverse drug reaction reporting by health workers in Uganda: a qualitative study. Drug Safety, 46(6), pp.565-574.","journal-title":"Drug Saf"},{"key":"11592_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-017-2009-6","volume":"17","author":"H Zakumumpa","year":"2017","unstructured":"Zakumumpa H, Bennett S, Ssengooba F. Alternative financing mechanisms for ART programs in health facilities in Uganda: a mixed-methods approach. BMC Health Serv Res. 2017;17:1\u20131.","journal-title":"BMC Health Serv Res"},{"key":"11592_CR11","doi-asserted-by":"crossref","unstructured":"Belete TM. Recent progress in the development of new antimalarial drugs with novel targets. Drug design, development and therapy. 2020 Sep 22:3875\u201389.","DOI":"10.2147\/DDDT.S265602"},{"issue":"3","key":"11592_CR12","doi-asserted-by":"publisher","first-page":"e067377","DOI":"10.1136\/bmjopen-2022-067377","volume":"13","author":"R Ndejjo","year":"2023","unstructured":"Ndejjo R, Chen N, Kabwama SN, Namale A, Wafula ST, Wanyana I, et al. Uptake of COVID-19 vaccines and associated factors among adults in Uganda: a cross-sectional survey. BMJ Open. 2023;13(3):e067377.","journal-title":"BMJ Open"},{"key":"11592_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06933-8","volume":"21","author":"H Zakumumpa","year":"2021","unstructured":"Zakumumpa H, Kitutu FE, Ndagije HB, Diana NK, Ssanyu JN, Kiguba R. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after National roll-out in Uganda: a qualitative study. BMC Infect Dis. 2021;21:1\u20133.","journal-title":"BMC Infect Dis"},{"key":"11592_CR14","unstructured":"Hunter D, McCallum J, Howes D. Defining exploratory-descriptive qualitative (EDQ) research and considering its application to healthcare. J Nurs Health Care. 2019;4(1).\u00a0https:\/\/dl6.globalstf.org\/index.php\/jnhc\/article\/view\/1975"},{"key":"11592_CR15","unstructured":"National Drug Authority. National Pharmacovigilance Bulletin 2023\u20132024. Accessed from https:\/\/www.nda.or.ug\/wp-content\/uploads\/2024\/10\/Annual-Pharmacovigilance-Report-2023-2024_compressed.pdf"},{"key":"11592_CR16","first-page":"100639","volume":"19","author":"E Moyo","year":"2023","unstructured":"Moyo E, Moyo P, Mangoya D, Imran M, Dzinamarira T. Adverse drug reaction reporting by healthcare providers in sub-Saharan africa: A scoping review of the challenges faced and the strategies to address the challenges. Int J Afr Nurs Sci. 2023Nov;19:100639.","journal-title":"Int J Afr Nurs Sci."},{"issue":"1","key":"11592_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MA, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17(1):75.","journal-title":"Implement Sci"},{"key":"11592_CR18","unstructured":"National Drug Authority. National Pharmacovigilance Bulletin. (2022). Accessed from https:\/\/www.nda.or.ug\/wp-content\/uploads\/2022\/08\/NDA-Pharmacovigilance-Bulletin-2022-Volume-14.pdf"},{"issue":"4","key":"11592_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1469-5812.2010.00720.x","volume":"44","author":"CJ Lee","year":"2012","unstructured":"Lee CJ. Reconsidering constructivism in qualitative research. Educ Philos Theory. 2012;44(4):403\u201312.","journal-title":"Educ Philos Theory"},{"key":"11592_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-9276-12-18","volume":"12","author":"JF Levesque","year":"2013","unstructured":"Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health. 2013;12:1\u20139.","journal-title":"Int J Equity Health"},{"issue":"1","key":"11592_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-022-07673-z","volume":"22","author":"H Zakumumpa","year":"2022","unstructured":"Zakumumpa H, Kiguba R, Ndagije HB, Ategeka G, Ssanyu JN, Kitutu FE. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study. BMC Infect Dis. 2022;22(1):1\u20131.","journal-title":"BMC Infect Dis"},{"key":"11592_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056039","author":"R Kiguba","year":"2022","unstructured":"Kiguba R, Ndagije HB, Nambasa V, Katureebe C, Zakumumpa H, Nanyonga SM, et al. Implementation of a peer support intervention to promote the detection, reporting and management of adverse drug reactions in people living with HIV in Uganda: a protocol for a quasi-experimental study. BMJ Open. 2022. https:\/\/doi.org\/10.1136\/bmjopen-2021-056039.","journal-title":"BMJ Open"},{"issue":"12","key":"11592_CR23","first-page":"1460","volume":"44","author":"H Zakumumpa","year":"2021","unstructured":"Zakumumpa H. Exploring the feasibility of the uptake of the med safety app in ADRs reporting in Uganda: a qualitative study. Drug Saf. 2021;44(12):1460.","journal-title":"Drug Saf"},{"key":"11592_CR24","unstructured":"Miles MB, Huberman AM. Qualitative data analysis: An expanded sourcebook. sage; 1994 Jan 12."},{"issue":"1","key":"11592_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80\u201392.","journal-title":"Int J Qual Methods"},{"issue":"7","key":"11592_CR26","doi-asserted-by":"publisher","first-page":"e0254214","DOI":"10.1371\/journal.pone.0254214","volume":"16","author":"H Zakumumpa","year":"2021","unstructured":"Zakumumpa H, Makobu K, Ntawiha W, Maniple E. A mixed-methods evaluation of the uptake of novel differentiated ART delivery models in a National sample of health facilities in Uganda. PLoS One. 2021;16(7):e0254214.","journal-title":"PLoS One"},{"issue":"10","key":"11592_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/2042098618790209","volume":"9","author":"S Ali","year":"2018","unstructured":"Ali S, Egunsola O, Al-Dossari DS, Al-Zaagi IA. Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Ther Adv Drug Saf. 2018;9(10):585\u201390.","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"11592_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/jep.12780","volume":"23","author":"F Chang","year":"2017","unstructured":"Chang F, Xi Y, Zhao J, Zhang X, Lu Y. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. J Eval Clin Pract. 2017;23(6):1316\u201321.","journal-title":"J Eval Clin Pract"},{"issue":"8","key":"11592_CR29","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/bcp.15791","volume":"89","author":"PA Routledge","year":"2023","unstructured":"Routledge PA, Bracchi R. Improving the spontaneous reporting of suspected adverse drug reactions: an overview of systematic reviews. Br J Clin Pharmacol. 2023;89(8):2377\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"11592_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/hiv.13761","volume":"26","author":"EA Odongpiny","year":"2025","unstructured":"Odongpiny EA, Nicol M, Katana E, Owori J, Buzibye A, Sedan K, Kesby M, Holden M, Owarwo N, Meya D, Castelnuovo B. A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda. HIV Med. 2025Jan 24;26(4):592\u2013605.","journal-title":"HIV Med"},{"key":"11592_CR31","unstructured":"Wadesango L. Dolutegravir Reported Adverse Drug Reactions: A Systematic Review (Master\u2019s thesis, University of the Witwatersrand, Johannesburg (South Africa). https:\/\/www.proquest.com\/openview\/3d88e4866671d510b1720e00ebb75c4b\/1?cbl=2026366&diss=y&pq-origsite=gscholar"},{"key":"11592_CR32","doi-asserted-by":"publisher","DOI":"10.11604\/pamj-cm.2022.8.47.33930","volume":"8","author":"MA Adeiza","year":"2022","unstructured":"Adeiza MA, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings: case report. PAMJ Clin Med. 2022;8:47.","journal-title":"PAMJ Clin Med"},{"issue":"5","key":"11592_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/09540121.2022.2062289","volume":"35","author":"JC Mendes","year":"2023","unstructured":"Mendes JC, Ceccato MD, Reis AM, Costa AM, Pantuzza LL, Furtado dos Santos S, Crepalde-Ribeiro K, Silveira MR. Active pharmacovigilance project on the safety profile of dolutegravir in Brazil. AIDS Care. 2023;35(5):729\u201338.","journal-title":"AIDS Care"},{"issue":"12","key":"11592_CR34","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","volume":"70","author":"NS van De Ven","year":"2020","unstructured":"van De Ven NS, Pozniak AL, Levi JA, Clayden P, Garratt A, Redd C, et al. Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy. Clin Infect Dis. 2020;70(12):2599\u2013606.","journal-title":"Clin Infect Dis"},{"issue":"1s","key":"11592_CR35","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.5530\/ijper.58.1s.2","volume":"58","author":"K Sulakhiya","year":"2024","unstructured":"Sulakhiya K, Kanchan S, Ansari H, Kisku A. Role of social media for drug safety signal detection. Ind J Pharm Educ Res. 2024;58(1s):s9-25.","journal-title":"Ind J Pharm Educ Res"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11592-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11592-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11592-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:05:43Z","timestamp":1762164343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11592-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11592"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11592-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received ethical approval from The AIDS Support Organization (TASO) Uganda Research Ethics Committee under instrument: TASO-2024-385. TASO REC is accredited by the Uganda National Council of Science and Technology (UNCST). All participants signed a written consent form before participating in the study. Data were collected in accordance with international conventions and guidelines on research involving human subjects such as the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1475"}}